Who are Aczone Gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dapsone 7.5 % gel, ACZONE Gel, 5%, Dapsone plus Adapalene, dapsone gel vehicle, Dapsone 5.0% Gel (SEEGPharm), Dapsone (Disulone®).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aczone-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Aczone Gel — Competitive Intelligence Brief

Aczone Gel (Aczone Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfone antibiotic. Area: Dermatology.

marketed Sulfone antibiotic Bacterial dihydropteroate synthase; neutrophil function modulation Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Aczone Gel (Aczone Gel) — Icahn School of Medicine at Mount Sinai. Dapsone reduces inflammation and bacterial growth in acne lesions through its antimicrobial and anti-inflammatory properties.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Aczone Gel TARGET	Aczone Gel	Icahn School of Medicine at Mount Sinai	marketed	Sulfone antibiotic	Bacterial dihydropteroate synthase; neutrophil function modulation
Dapsone 7.5 % gel	Dapsone 7.5 % gel	Derm Research, PLLC	marketed	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase; neutrophil function and inflammatory mediators
ACZONE Gel, 5%	ACZONE Gel, 5%	Allergan	marketed	Sulfone antibiotic	Bacterial dihydropteroate synthase; neutrophil-mediated inflammation
Dapsone plus Adapalene	Dapsone plus Adapalene	Allergan	marketed	Retinoid plus sulfone antibiotic combination	Retinoic acid receptors (adapalene); dihydrofolate reductase inhibition and neutrophil suppression (dapsone)
dapsone gel vehicle	dapsone gel vehicle	Almirall, S.A.	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase; neutrophil function modulation
Dapsone 5.0% Gel (SEEGPharm)	Dapsone 5.0% Gel (SEEGPharm)	Seegpharm S.A.	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase (bacterial); neutrophil function and ROS production (host)
Dapsone (Disulone®)	Dapsone (Disulone®)	Assistance Publique - Hôpitaux de Paris	phase 3	Sulfone antibiotic with immunomodulatory properties	Dihydrofolate reductase; neutrophil function and complement pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfone antibiotic class)

Allergan · 1 drug in this class
Icahn School of Medicine at Mount Sinai · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aczone Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/aczone-gel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab